Developing recombinant human Leptin as a therapy for Alzheimer's Disease (AD) and as a preventative for those at risk. The human hormone and protein Leptin has a large number of receptors in the brain’s memory centers. The protein’s levels often decline in AD patients, and their cognitive deterioration correlates strongly with a decrease in Leptin circulation. The protein is neuroprotective, improves cognition and Neurotez expects it to reduce the pathological hallmarks of Alzheimer’s disease – plaques and tangles. Leptin replacement therapy represents a relatively risk-reduced approach to drug development.
Developing a recombinant human Leptin therapy for Alzheimer's Disease and as a preventative for those at risk
Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers. Currently, drug delivery to the brain and spinal cord requires oral or intravenous administration. In all such systemic approaches, the blood brain barrier significantly hampers efficacy. Nasal brain delivery bypasses this inhibitor with direct, non-invasive access. NeOnc Technologies (NTI) is working in partnership with a pharmaceutical company to conduct a Phase I/II trial on their lead compound NEO100, for patients suffering recurrent, malignant gliomas.
Developing a therapeutic using perillyl alcohol for intranasal treatment of brain-related and respiratory cancers
Rapidly develop more effective, individualized therapies for people with epilepsy and other neurological disorders. Focusing on genetically-based epilepsies, Intellimedix designs and applies innovative technologies and models to identify new protocols. It repurposes existing drugs and seeks out new compounds that can personalize disease treatment.
Rapidly develop more effective, individualized therapies for people with epilepsy and other neurological disorders
This proprietary device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year. 80% of all children under the age of three suffer from this ailment, and current U.S. CPT reimbursement represents a $4 billion domestic opportunity. Worldwide, the potential rises to $40 billion for the disposable component of Entra Tympanic’s EToscope™.
Device allows safe, in-office treatment of middle ear infections that affects 28M people in the US every year
Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy. Success with drugs that treat a range of catastrophic, Orphan epilepsies like Infantile Spasms and Lennox Gastaut Syndrome, Insero intends a therapy for Dravet Syndrome to become its first clinical candidate compound. The company has used recent, molecular learning to screen and develop compounds which control seizures in animal models of Dravet.
Develop therapeutics from natural products to address unmet needs in neurological diseases like epilepsy
AblaCor’s proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF). The progressive impact of AF affects an estimated 6M people in the US and tens of millions worldwide. While traditional Pulmonary Vein Isolation for AF often requires repeated procedures, AblaCor’s CircumBlator™ maximizes ablator-tissue contact for a one-touch solution.
Proprietary ablation catheter technology offers more effective treatment of atrial fibrillation (AF)
New antibiotics target life-threatening infections of drug-resistant organisms like Pseudomonas and Acinetobacter. The Company has developed two distinct classes of compounds and a platform technology. Together, these enable Hsiri to use existing generic drugs to develop new antibiotics directed at specific bacteria species (also including Mycobacterium avium). The U.S. market for these antibiotics exceeds $3 billion.
New antibiotics target life-threatening infections of drug-resistant organisms like Pseudomonas and Acinetobacter
Combine advanced diagnostics and proprietary drugs to target ADPKD and p-STAT3 mediated cancers. The company is developing STAT3 inhibitors for ADPKD. These inhibitors also work particularly in reversing cancer cells resistant to chemotherapy. No alternatives currently exist for either condition, and GLG’s protocol can both improve quality of life and extend lifespan by 10-15 years.
Combine advanced diagnostics and proprietary drugs to target ADPKD and p-STAT3 mediated cancers
Our online marketplace introduces you to private companies looking to transform healthcare. By expanding the number of accredited investors a private company can have, the JOBS Act makes these investment opportunities available at lower minimums.
Watch CEO Greg Simon Explain the Importance of Poliwogg, the Crowd and Investing in Young Healthcare Companies - July 6, 2013
Welcome to Poliwogg, an innovative financial firm transforming healthcare investing. We provide pathways for accredited investors to invest in early stage companies in health and life sciences, structure indexes that measure the impact of public companies in health, and are launching sector specific publicly registered venture funds focused by health vertical. Our mission is to transform...MORE
Eager to “democratize” healthcare investing, Poliwogg gives the crowd new ways to join inMORE
SoCalBio Elects Veteran Life Sciences Investor Joseph A. Boystak to Board of DirectorsMORE
Poliwogg Announces Partnerships with Epilepsy Foundation and Alpha-1 Project; Names Dennis Purcell Special AdvisorMORE
The Alpha-1 Project and Poliwogg Form Partnership To Find Therapies, Cures for Alpha-1 Antitrypsin DeficiencyMORE